Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients
| العنوان: | Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients |
|---|---|
| المؤلفون: | Annamaria Colao, Libuse Tauchmanovà, Gaetano De Rosa, Gelsomina Mansueto, Antongiulio Faggiano, Marialaura Del Basso De Caro, Valeria Ramundo, Gaetano Lombardi, Lidice Brandao Tavares, Francesco Milone |
| المساهمون: | Faggiano, Antongiulio, L. B., Tavare, L., Tauchmanovà, Milone, Francesco, G., Mansueto, V., Ramundo, DEL BASSO DE CARO, Marialaura, G., Lombardi, DE ROSA, Gaetano, Colao, Annamaria |
| المصدر: | Clinical Endocrinology. 69:756-762 |
| بيانات النشر: | Wiley, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Adult, Male, Parathyroidectomy, endocrine system, medicine.medical_specialty, Hypercalcaemia, Antineoplastic Agents, Hormonal, endocrine system diseases, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Octreotide, Antineoplastic Agents, Drug Administration Schedule, Young Adult, Endocrinology, Duodenal Neoplasms, Internal medicine, Multiple Endocrine Neoplasia Type 1, medicine, Humans, multiple endocrine neoplasia, Hypercalciuria, Aged, Hyperparathyroidism, Hormonal, business.industry, Somatostatin receptor, Delayed-Action Preparations, Female, Hyperparathyroidism, Primary, Middle Aged, Neuroendocrine Tumors, Pancreatic Neoplasms, Somatostatin, medicine.disease, MEN1, business, Primary, hormones, hormone substitutes, and hormone antagonists, Primary hyperparathyroidism, medicine.drug |
| الوصف: | Background In patients with multiple endocrine neoplasia type 1 (MEN1), expression of somatostatin receptor (SST) in parathyroid adenomas and effectiveness of therapy with somatostatin analogues on primary hyperparathyroidism (PHP) have been scarcely investigated. Objective To evaluate the effects of depot long acting octreotide (OCT-LAR) in patients with MEN1-related PHP. Patients Eight patients with a genetically confirmed MEN1, presenting both PHP and duodeno-pancreatic neuroendocrine tumours (NET), were enrolled. Design The initial treatment was OCT-LAR 30 mg every 4 weeks. This therapy was established to stabilize the duodeno-pancreatic NET before to perform parathyroidectomy for PHP. Before OCT-LAR therapy, a SST scintigraphy was performed in all patients. SST subtype 2A immunohistochemistry was performed on parathyroid tumour samples from three patients undergone parathyroidectomy after OCT-LAR therapy. Measurements Serum concentrations of PTH, calcium and phosphorus as well as the 24-h urine calcium : creatinine ratio and the renal threshold phosphate concentration were evaluated before and after OCT-LAR. Results After OCT-LAR therapy, hypercalcaemia and hypercalciuria normalized in 75% and 62.5% of patients, respectively, and serum phosphorus and renal threshold phosphate significantly increased. Serum PTH concentrations significantly decreased in all patients and normalized in two of them. SST subtype 2A immunostaining was found in all parathyroid adenomas investigated, while SST scintigraphy showed a positive parathyroid tumour uptake in three of eight patients (37.5%). Conclusion Six months of OCT-LAR therapy controlled hypercalcaemia and hypercalciuria in two-thirds of patients with MEN1-related PHP. Direct OCT-LAR effects mediated by binding to SST expression on parathyroid tumour cells are likely the main mechanism to explain the activity of this compound on calcium and phosphorus abnormalities in MEN1 PHP. |
| وصف الملف: | STAMPA |
| تدمد: | 1365-2265 0300-0664 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b7529ccb7ca2024e813b4a9c5e899e https://doi.org/10.1111/j.1365-2265.2008.03301.x |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....54b7529ccb7ca2024e813b4a9c5e899e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652265 03000664 |
|---|